T1	And 31 35	with
E1	And:T1
T2	Modifier 36 43	chronic
E2	Modifier:T2
T3	Condition 44 55	anovulation
E3	Condition:T3 Name:T78
T4	Or 56 58	or
E4	Or:T4
T5	Condition 59 73	oligomenorrhea
E5	Condition:T5 Name:T79
T6	Condition 85 111	spontaneous intermenstrual
E6	Condition:T6 Name:T80
T7	Eq-Comparison 123 155	greater than or equal to 45 days
E7	Eq-Comparison:T7 Operator:T81 Value:T82 Temporal-Unit:T83
T8	Or 156 158	or
E8	Or:T8
T9	Eq-Comparison 170 209	less than or equal to 8 menses per year
E9	Eq-Comparison:T9 Operator:T84 Operator:T85 Value:T86 Temporal-Unit:T88
T10	And 222 226	with
E10	And:T10
T11	Condition 227 243	Hyperandrogenism
E11	Condition:T11 Name:T90
T12	Observation 257 275	total testosterone
E12	Observation:T12 Name:T91
T13	Eq-Comparison 276 297	greater than 50 ng/dL
E13	Eq-Comparison:T13 Operator:T92 Value:T93 Unit:T94 Unit:T95
T14	Or 298 300	or
E14	Or:T14
T15	Observation 303 322	free androgen index
E15	Observation:T15 Name:T96
T16	Eq-Comparison 323 338	greater than 10
E16	Eq-Comparison:T16 Operator:T97 Value:T98
T17	And 351 355	with
E17	And:T17
T18	Condition 356 374	Polycystic Ovaries
E18	Condition:T18 Name:T100
T19	Procedure 378 388	Ultrasound
E19	Procedure:T19 Name:T101
T20	Eq-Comparison 400 417	either 12 or more
E20	Eq-Comparison:T20 Value:T102 Operator:T103
T21	Observation 418 437	follicles measuring
E21	Observation:T21 Name:T104
T22	Eq-Comparison 438 444	2-9 mm
E22	Eq-Comparison:T22 Value:T105 Operator:T106 Value:T107 Unit:T108
T23	Modifier 448 456	diameter
E23	Modifier:T23
T24	Or 457 459	or
E24	Or:T24
T25	Observation 470 484	ovarian volume
E25	Observation:T25 Name:T110
T26	Eq-Comparison 485 503	greater than 10 cm
E26	Eq-Comparison:T26 Operator:T111 Value:T112 Unit:T113
T27	And 536 540	with
E27	And:T27
T28	Condition 541 559	Hyperprolactinemia
E28	Condition:T28 Name:T115
T29	Observation 573 589	prolactin levels
E29	Observation:T29 Name:T116
T30	Eq-Comparison 590 636	at least one week apart greater than 30 ng/mL.
E30	Eq-Comparison:T30 Operator:T117 Value:T118 Temporal-Unit:T119 Operator:T120 Value:T121 Unit:T122 Unit:T123
T31	And 648 652	with
E31	And:T31
T32	Condition 659 684	21-hydroxylase deficiency
E32	Condition:T32 Name:T125
T33	Or 685 687	or
E33	Or:T33
T34	Other 688 693	other
E34	Other:T34
T35	Condition 694 711	enzyme deficiency
E35	Condition:T35 Name:T126
T36	Exception 712 722	leading to
E36	Exception:T36
T37	Condition 727 757	congenital adrenal hyperplasia
E37	Condition:T37 Name:T127
T38	And 770 774	with
E38	And:T38
T39	Observation 784 794	FSH levels
E39	Observation:T39 Name:T130
T40	Eq-Comparison 795 818	greater than 10 mIU/mL.
E40	Eq-Comparison:T40 Operator:T131 Value:T132 Unit:T133 Unit:T134
T41	And 830 834	with
E41	And:T41
T42	Condition 835 862	uncorrected thyroid disease
E42	Condition:T42 Name:T136
T43	Observation 912 915	TSH
E43	Observation:T43 Name:T138
T44	Eq-Comparison 916 937	less than 0.45 mIU/mL
E44	Eq-Comparison:T44 Operator:T139 Value:T140 Unit:T141 Unit:T142
T45	Or 938 940	or
E45	Or:T45
T46	Eq-Comparison 941 964	greater than 4.5 MIU/mL
E46	Eq-Comparison:T46 Operator:T143 Value:T144 Unit:T145 Unit:T146
T47	And 978 982	with
E47	And:T47
T48	Assertion 985 994	suspected
E48	Assertion:T48
A1	Assertion-Type-Value E48 possible
T49	Modifier 995 1002	adrenal
E49	Modifier:T49
T50	Or 1003 1005	or
E50	Or:T50
T51	Modifier 1006 1013	ovarian
E51	Modifier:T51
T52	Condition 1014 1019	tumor
E52	Condition:T52 Name:T148
T53	Drug 1020 1039	secreting androgens
E53	Drug:T53 Name:T149
T54	And 1051 1055	with
E54	And:T54
T55	Condition 1056 1074	Cushing's syndrome
E55	Condition:T55 Name:T151
T56	Eq-Comparison 1086 1088	on
E56	Eq-Comparison:T56
T57	Drug 1101 1112	medications
E57	Drug:T57
T58	Condition 1126 1142	ovarian function
E58	Condition:T58 Name:T154
T59	Drug 1153 1162	metformin
E59	Drug:T59 Name:T155
T60	Drug 1164 1187	hormonal contraceptives
E60	Drug:T60 Name:T156
T61	Or 1188 1190	or
E61	Or:T61
T62	Other 1191 1196	other
E62	Other:T62
T63	Drug 1197 1208	medications
E63	Drug:T63
T64	Condition 1213 1228	type 2 diabetes
E64	Condition:T64 Name:T157
T65	And 1240 1244	with
E65	And:T65
T66	Condition 1245 1263	medical conditions
E66	Condition:T66
T67	Contraindication 1273 1290	contraindications
E67	Contraindication:T67
T68	Drug 1294 1306	OTC inositol
E68	Drug:T68 Name:T159
T69	Or 1307 1309	or
E69	Or:T69
T70	Eq-Comparison 1310 1318	previous
E70	Eq-Comparison:T70 Temporal-Period:T160
T71	Allergy 1319 1327	allergic
E71	Allergy:T71
T72	Drug 1345 1355	supplement
E72	Drug:T72
T73	Or 1356 1358	or
E73	Or:T73
T74	Drug 1366 1386	placebo maltodextrin
E74	Drug:T74 Name:T161
T75	Or 1387 1389	or
E75	Or:T75
T76	Drug 1390 1396	inulin
E76	Drug:T76 Name:T162
T77	Life-Stage-And-Gender 25 30	Women
A2	Life-Stage-And-Gender-Type T77 female
T78	Condition-Name 44 55	anovulation
T79	Condition-Name 59 73	oligomenorrhea
T80	Condition-Name 85 111	spontaneous intermenstrual
T81	Eq-Operator 123 144	greater than or equal
A3	Eq-Operator-Value T81 GTEQ
T82	Eq-Value 148 150	45
T83	Eq-Temporal-Unit 151 155	days
A4	Eq-Temporal-Unit-Value T83 day
T84	Eq-Operator 170 179	less than
A5	Eq-Operator-Value T84 LT
T85	Eq-Operator 180 188	or equal
A6	Eq-Operator-Value T85 GTEQ
T86	Eq-Value 192 193	8
T87	Observation-Name 194 200	menses
A7	Observation-Type-Value T87 measurement
T88	Eq-Temporal-Unit 205 209	year
A8	Eq-Temporal-Unit-Value T88 year
T89	Life-Stage-And-Gender 216 221	Women
A9	Life-Stage-And-Gender-Type T89 female
T90	Condition-Name 227 243	Hyperandrogenism
T91	Observation-Name 257 275	total testosterone
A10	Observation-Type-Value T91 lab
T92	Eq-Operator 276 288	greater than
A11	Eq-Operator-Value T92 GT
T93	Eq-Value 289 291	50
T94	Eq-Unit 292 294	ng
T95	Eq-Unit 295 297	dL
T96	Observation-Name 303 322	free androgen index
A12	Observation-Type-Value T96 lab
T97	Eq-Operator 323 335	greater than
A13	Eq-Operator-Value T97 GT
T98	Eq-Value 336 338	10
T99	Life-Stage-And-Gender 345 350	Women
A14	Life-Stage-And-Gender-Type T99 female
T100	Condition-Name 356 374	Polycystic Ovaries
T101	Procedure-Name 378 388	Ultrasound
T102	Eq-Value 407 409	12
T103	Eq-Operator 410 417	or more
A15	Eq-Operator-Value T103 GTEQ
T104	Observation-Name 418 437	follicles measuring
A16	Observation-Type-Value T104 measurement
T105	Eq-Value 438 439	2
T106	Eq-Operator 439 440	-
A17	Eq-Operator-Value T106 BETWEEN
T107	Eq-Value 440 441	9
T108	Eq-Unit 442 444	mm
T109	Polarity 460 469	increased
A18	Polarity-Value T109 high
T110	Observation-Name 470 484	ovarian volume
A19	Observation-Type-Value T110 measurement
T111	Eq-Operator 485 497	greater than
A20	Eq-Operator-Value T111 GT
T112	Eq-Value 498 500	10
T113	Eq-Unit 501 503	cm
T114	Life-Stage-And-Gender 530 535	Women
A21	Life-Stage-And-Gender-Type T114 female
T115	Condition-Name 541 559	Hyperprolactinemia
T116	Observation-Name 573 589	prolactin levels
A22	Observation-Type-Value T116 lab
T117	Eq-Operator 590 598	at least
A23	Eq-Operator-Value T117 GTEQ
T118	Eq-Value 599 602	one
T119	Eq-Temporal-Unit 603 607	week
A24	Eq-Temporal-Unit-Value T119 week
T120	Eq-Operator 614 626	greater than
A25	Eq-Operator-Value T120 GT
T121	Eq-Value 627 629	30
T122	Eq-Unit 630 632	ng
T123	Eq-Unit 633 636	mL.
T124	Life-Stage-And-Gender 642 647	Women
A26	Life-Stage-And-Gender-Type T124 female
T125	Condition-Name 659 684	21-hydroxylase deficiency
T126	Condition-Name 694 711	enzyme deficiency
T127	Condition-Name 727 757	congenital adrenal hyperplasia
T128	Life-Stage-And-Gender 764 769	Women
A27	Life-Stage-And-Gender-Type T128 female
T129	Polarity 775 783	elevated
A28	Polarity-Value T129 high
T130	Observation-Name 784 794	FSH levels
A29	Observation-Type-Value T130 lab
T131	Eq-Operator 795 807	greater than
A30	Eq-Operator-Value T131 GT
T132	Eq-Value 808 810	10
T133	Eq-Unit 811 814	mIU
T134	Eq-Unit 815 818	mL.
T135	Life-Stage-And-Gender 824 829	Women
A31	Life-Stage-And-Gender-Type T135 female
T136	Condition-Name 847 862	thyroid disease
T137	Condition-Name 870 874	ASRM
T138	Observation-Name 912 915	TSH
A32	Observation-Type-Value T138 lab
T139	Eq-Operator 916 925	less than
A33	Eq-Operator-Value T139 LT
T140	Eq-Value 926 930	0.45
T141	Eq-Unit 931 934	mIU
T142	Eq-Unit 935 937	mL
T143	Eq-Operator 941 953	greater than
A34	Eq-Operator-Value T143 GT
T144	Eq-Value 954 957	4.5
T145	Eq-Unit 958 961	MIU
T146	Eq-Unit 962 964	mL
T147	Life-Stage-And-Gender 972 977	Women
A35	Life-Stage-And-Gender-Type T147 female
T148	Condition-Name 1014 1019	tumor
T149	Drug-Name 1020 1039	secreting androgens
T150	Life-Stage-And-Gender 1045 1050	Women
A36	Life-Stage-And-Gender-Type T150 female
T151	Condition-Name 1056 1074	Cushing's syndrome
T152	Life-Stage-And-Gender 1080 1085	Women
A37	Life-Stage-And-Gender-Type T152 female
T153	Stability 1119 1125	affect
A38	Stability-Value T153 change
T154	Condition-Name 1126 1142	ovarian function
T155	Drug-Name 1153 1162	metformin
T156	Drug-Name 1164 1187	hormonal contraceptives
T157	Condition-Name 1213 1228	type 2 diabetes
T158	Life-Stage-And-Gender 1234 1239	Women
A39	Life-Stage-And-Gender-Type T158 female
T159	Drug-Name 1294 1306	OTC inositol
T160	Eq-Temporal-Period 1310 1318	previous
A40	Eq-Temporal-Period-Value T160 past
T161	Drug-Name 1366 1386	placebo maltodextrin
T162	Drug-Name 1390 1396	inulin